ClinicalTrials.gg
RecruitingNCT06152289NOCEUpdated Mar 2, 2026

Development of New Diagnostic Tools in Capsule Endoscopy

An observational study in Bowel Disease, Crohn Disease and Celiac Disease, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Intestinal Diseases with a site in France — 6 open to participants now, 8 under way, 3 of them phase 3. Intestinal Diseases · France.

Started
2023
with 1 other
Observational
2 of 22
2 open now
Registered
18th of 22
by date
Lead sponsor
3 of 22
Assistance Publique - Hôpitaux de Paris

Among the 22 studies in Intestinal Diseases with a site in France, this one is one of 2 that started in 2023, is one of 2 observational ones, and was the 18th registered.

Intestinal Diseases

260 studies on the registry are indexed under Intestinal Diseases; 53 are open to participants now.

Browse Intestinal Diseases studies →

Open to participants now

6 of the 22 studies in Intestinal Diseases with a site in France are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 38 Intestinal Diseases studies recruiting now, 17 (45%) set no upper age limit and 17 (45%) stop at 75 or younger; 15 take children under 18; 6 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Intestinal Diseases with a site in France, or all of them as a file.
02

Study summary

Patients participating to this study will provide images and videos of capsule endoscopy to train, tune and evaluate technological bricks of artificial intelligence solutions, in order to improve diagnostic performances of the procedure, while reducing reading time by physicians.

Read the detailed description

Capsule endoscopy is a minimally-invasive diagnostic procedure based on the ingestion (or endoscopic delivery) of a miniaturized biocompatible, camera. Capsules capture tenths of thousands images of the digestive tract. Reading the captured images and reporting is long, tedious, and at risk of errors when the reader's attention is disturbed. Artificial intelligence is expected to alleviate these limitations, by both improving diagnostic performances of capsule endoscopy while reducing reading time.

Any patient in whom a capsule endoscopy examination is performed as part of routine care will be invited to participate to the study. Their de-identified images and videos will be extracted, thus allowing the creation of several databases for training, tuning and testing technological bricks of artificial intelligence. Basic clinical data will be collected (age, gender, indication for capsule endoscopy, type of device, ingestion or delivery of capsule). Images and videos will be characterized centrally and consensually by a panel of 3 expert readers, according to their level of relevance in relation to the type and indication of capsule endoscopy.

The various, developed technological bricks will aim to automatically detect and characterize anatomical landmarks and abnormal findings, and to quote the intestine cleanliness.

Assessment of diagnostic performance and reading time will be performed within a few months or up to five years, for each technological brick, individually and then combined, according to their stepwise development.

03

Conditions studied

  • Bowel Disease
  • Crohn Disease
  • Celiac Disease
  • Chronic Diarrhea
  • Tumor

Keywords

  • Small bowel
  • Capsule endoscopy
  • Artificial intelligence
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Any patient in whom a capsule endoscopy examination is performed as part of routine care

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Any patient in whom a capsule endoscopy examination is performed as part of routine care.

Exclusion criteria

Exclusion Criteria:

- Opposition to the use of images and videos from daily, routine care for research purposes.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Develop an artificial intelligence solution to help with diagnosis in VCE

    Sensitivity in detection of lesions of intermediate to high relevance as identified centrally and consensually by a panel of 3 expert readers (AI vs standard reading)

    Time frame: Through study completion, 5 years

Secondary outcomes

  1. Evaluation of the diagnostic performance of the A.I. solution in terms of detection

    Other diagnostic performance (specificity, positive and negative predictive values, accuracy) in detection of lesions of intermediate to high relevance as identified centrally and consensually by a panel of 3 expert readers (AI vs standard reading)

    Time frame: Through study completion, 5 years

  2. Evaluation of the diagnostic performance of the A.I. solution in terms of characterisation

    Time needed for detection of lesions of intermediate to high relevance as identified centrally and consensually by a panel of 3 expert readers (AI vs standard reading)

    Time frame: Through study completion, 5 years

  3. Evaluation of the diagnostic performance of the A.I. solution in terms of recognition of anatomical landmarks

    Diagnostic performances in positioning anatomical landmarks (1st gastric, small bowl and colonic images) as identified centrally and consensually by a panel of 3 expert readers (AI vs standard reading)

    Time frame: Through study completion, 5 years

  4. Evaluation of the diagnostic performance of the A.I. solution in terms of quality of preparation of the various segments of the digestive tract

    Diagnostic performances in quoting small bowel and colonic quality of preparation, as compared toed centrally and consensually quoted by a panel of 3 expert readers

    Time frame: Through study completion, 5 years

07

Study locations

1 of 1 sites recruiting
  • Centre d'Endoscopie Digestive Hôpital Saint-Antoine
    Paris, 75012, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Feb 2028, 60 months after the start.

Of 35 observational studies under Intestinal Diseases, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 102. This study's planned 60 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2023
First posted
Nov 30, 2023
StartActual
Feb 10, 2023
Primary completionEst.
Feb 2028
CompletionEst.
Feb 2028
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06152289
Responsible party
Sponsor
First posted
Nov 30, 2023
Start date
Feb 10, 2023
Primary completion
Feb 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Mar 2, 2026

Study contacts

Xavier DRAY, MD PhD
Contact
Xavier.dray@aphp.fr
+33 (0) 49 28 21 60
Romain LEENHARDT, MD
Contact
romain.leenhardt@aphp.fr
+33 (0) 1 49 28 21 61

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion